Botulinum Toxin in Urology Market to Grow with Significant Share During 2023–2030 Forecast Period
Botulinum toxin in urology market is driven by the rising prevalence of urological disorders such as overactive bladder and neurogenic detrusor overactivity. Increasing adoption of minimally invasive treatment options, along with growing awareness of advanced therapeutic procedures, is supporting market growth across healthcare systems. Additionally, improvements in clinical efficacy and expanding applications of botulinum toxin in urology are further strengthening its demand in hospitals and specialized urology clinics worldwide.
Browse the full report description of “Botulinum Toxin in Urology Market Size, Share & Trends Analysis Report, By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-User (Hospitals, Urology Clinics), Forecast Period (2023–2030)” at https://www.omrglobal.com/industry-reports/botulinum-toxin-in-urology-market
Botulinum toxin A in idiopathic overactive bladder: narrative review (2025)
A comprehensive narrative review published in 2025 evaluated 31 studies involving 5,410 patients to assess the efficacy and safety of botulinum toxin A (BoNT-A) in idiopathic overactive bladder (OAB) after failure of conservative treatments. The findings confirm that BoNT-A significantly improves OAB symptoms, including after repeated reinjections. H`owever, increasing doses does not improve therapeutic efficacy and instead raises the risk of adverse events. Key adverse effects include elevated post-void residual (PVR), need for clean intermittent self-catheterization (CISC), and urinary tract infections (UTIs). The review also identified multiple predictive factors for complications and poor response, such as age, gender, prior pelvic surgeries, diabetes, and baseline urodynamic parameters. Overall, BoNT-A remains an effective treatment for refractory idiopathic OAB, particularly for incontinence, but its use requires careful patient selection due to dose-dependent safety limitations.
EU clinical adoption of intradetrusor botulinum toxin continues to rise (2024–2025)
Between 2024 and 2025, clinical adoption of intradetrusor botulinum toxin injections has continued to increase across European healthcare systems, supported by urology society guidelines and growing hospital-level integration. The therapy is increasingly used for managing overactive bladder (OAB) and neurogenic detrusor overactivity, particularly in patients who do not respond adequately to first-line anticholinergic medications. As a second-line treatment option, botulinum toxin is being more widely incorporated into routine urological practice due to its proven efficacy in symptom reduction, improved quality of life outcomes, and its minimally invasive nature compared to surgical alternatives.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404